Publications by Huw Thomas - ePrints

Browsing publications by Huw Thomas.

Newcastle Authors	Title	Year
Dr Celine Cano Professor Jane Endicott Dr Ian Hardcastle Dr Claire Jennings Suzanne Kyle et al.	Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile	2024
Dr Elaine Willmore Suzanne Kyle Dr Yan Zhao Huw Thomas Dr Kenneth Rankin et al.	Targeting the MDM2-p53 interaction: Time- and concentration-dependent studies in tumor and normal human bone marrow cells reveal strategies for an enhanced therapeutic index	2024
Dr Emma Scott Emily Archer Goode Rebecca Garnham Dr Kirsty Hodgson Maggie Orozco Moreno et al.	ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression	2023
Dr Nahoum Anthony Charlotte Jennings Dr Mathew Martin Dr Richard Noble Nicole Phillips et al.	Targeting cytotoxic agents through EGFR-mediated covalent binding and release	2023
Dr Kirsty Hodgson Maggie Orozco Moreno Dr Emma Scott Rebecca Garnham Karen Livermore et al.	The role of GCNT1 mediated O-glycosylation in aggressive prostate cancer	2023
Dr Emma Scott Dr Kirsty Hodgson Kat Cheung Edward Yo Laura Wilson et al.	Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth	2023
Dr Jill Hunter Dr Jacqueline Butterworth Helene Sellier Dr Nicola Hannaway Dr Saimir Luli et al.	Mutation of the RelA(p65) Thr505 phosphosite disrupts the DNA replication stress response leading to CHK1 inhibitor resistance	2022
Duncan Miller Tristan Reuillon Dr Lauren Molyneux Dr Tim Blackburn Dr Noel Edwards et al.	Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor	2022
Dr Richard Noble Huw Thomas Dr Yan Zhao Professor Steve Wedge	Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma	2022
Dr Marco Zaki Dr Sari Alhasan Dr Ruchi Shukla Misti McCain Maja Laszczewska et al.	Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?	2022
Dr Ian Hardcastle Dr Ruth Bawn Dr Tim Blackburn Dr Celine Cano Dr Sarah Cully et al.	Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction	2021
Alex Bainbridge Dr Scott Walker Joseph Smith Yi Min Ng Ng Huw Thomas et al.	IKBKE activity enhances AR levels in advanced prostate cancer via modulation of the Hippo pathway	2020
Liz Matheson Huw Thomas Marian Case Dr Helen Blair Rosanna Jackson et al.	Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood acute lymphoblastic leukemia through upregulation of BIM	2019
Stephanie Myers Duncan Miller Dr Lauren Molyneux Dr Mercedeh Arasta Dr Ruth Bawn et al.	Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4	2019
Dr Lindi Chen Philip Berry Dr Jennifer Bonner Calum Kirk Dr Katrina Wood et al.	Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma	2019
Dr Catherine Willoughby Huw Thomas Dr Elaine Willmore Suzanne Kyle Dr Anita Wittner et al.	Selective DNA-PKcs Inhibition Extends the Therapeutic Index of Localized Radiotherapy and Chemotherapy	2019
Dr Dominic Jones Laura Wilson Huw Thomas Dr Luke Gaughan Dr Mark Wade et al.	The histone demethylase enzymes KDM3A and KDM4B co-operatively regulate chromatin transactions of the estrogen receptor in breast cancer	2019
Lucy Gentles Dr Calum Kirk Huw Thomas Professor Steve Wedge Professor Nicola Curtin et al.	An investigation of the effect of tissue ischaemia upon DNA damage protein markers in ovarian cancer	2017
Dr Aiste McCormick Gavin Cuthbert Dr Rachel O'Donnell Dr Brian Wilson Huw Thomas et al.	Functional characterisation of a novel ovarian cancer cell line, NUOC-1	2017
Dr Richard Noble Dr Natalie Bell Dr Helen Blair Huw Thomas Nicole Phillips et al.	Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and burkitt lymphoma	2017
Carlo Bawn Dr Martin Galler Huw Thomas Suzanne Kyle Professor Nicola Curtin et al.	PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS	2017
Dr Christopher Wong Dr Ian Hardcastle Christopher Matheson Professor Herbie Newell Dr Mangaleswaran Sivaprakasam et al.	Structure-guided design of purine-based probes for selective Nek2 inhibition	2017
Dr Gary Beale Dr Emma Haagensen Huw Thomas Lan Wang Charlotte Revill et al.	Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo anti-tumour activity in colorectal cancer	2016
Dr Emma Haagensen Huw Thomas Dr Ross Maxwell Professor Herbie Newell	Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037	2016
Dr Emma Haagensen Huw Thomas Dr Ross Maxwell Professor Herbie Newell	Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent	2016
Dr Jill Hunter Dr Jacqueline Butterworth Helene Sellier Huw Thomas Dr Christopher Bacon et al.	The NF-κB subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma	2016
Liam Cornell Dr Joanne Martin Laura Ogle Dr Catherine Willoughby Dr Despina Televantou et al.	DNA-PK-A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival	2015
Huw Thomas Professor Nicola Curtin	Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself	2015
Dr Johnny Roughan Claire Coulter Emeritus Professor Paul Flecknell Huw Thomas	The Conditioned Place Preference Test for Assessing Welfare Consequences and Potential Refinements in a Mouse Bladder Cancer Model	2014
James Murray Huw Thomas Philip Berry Suzanne Kyle Dr Miranda Patterson et al.	Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules	2014
Dr Frida Ponthan Claire Whitworth Huw Thomas Dr Chris Redfern	Cell Survival Signalling through PPARδ and Arachidonic Acid Metabolites in Neuroblastoma	2013
Christopher Hill Dr David Jamieson Huw Thomas Dr Colin Brown Professor Alan Boddy et al.	Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo	2013
Dr Emma Haagensen Huw Thomas Ian Wilson Dr Suzannah Harnor Sara Payne et al.	The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [¹⁸F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice	2013
Dr Anastasia Hepburn Dr Stuart Williamson Dr Amira El-Sherif Dr Neha Sahay Huw Thomas et al.	Side Population in Human Non-Muscle Invasive Bladder Cancer Enriches for Cancer Stem Cells That Are Maintained by MAPK Signalling	2012
Dr Emma Meczes Huw Thomas Professor Richard Edmondson Professor Gareth Veal Professor Alan Boddy et al.	Therapy induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tumours	2012
Huw Thomas Professor Herbie Newell Professor Nicola Curtin	Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition	2011
Dr Kappusamy Saravanan Hannah Barlow Marion Barton Professor Hilary Calvert Emeritus Professor Bernard Golding et al.	Nucleoside Transport Inhibitors: Structure-Activity Relationships for Pyrimido[5,4-d]pyrimidine Derivatives That Potentiate Pemetrexed Cytotoxicity in the Presence of α₁-Acid Glycoprotein	2011
Tomasz Zaremba Huw Thomas Mike Cole Dr Sally Coulthard Professor Ruth Plummer et al.	Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers	2011
Huw Thomas Dr Celine Roche Dr Johanne Bentley Dr Ian Hardcastle Emeritus Professor Bernard Golding et al.	Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301	2011
Huw Thomas Suzanne Kyle Ivanda Pavlovska Professor Nicola Curtin	The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice	2011
Dr Yvette Drew Dr Evan Mulligan Wan Vong Huw Thomas Suzanne Kyle et al.	Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2	2011
Huw Thomas Suzanne Kyle Rafal Zur Dr Evan Mulligan Professor Nicola Curtin et al.	6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance	2010
Rachel Daniel Dr Agata Rozanska Dr Evan Mulligan Dr Yvette Drew Huw Thomas et al.	Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699	2010
Tomasz Zaremba Huw Thomas Mike Cole Professor Ruth Plummer Professor Nicola Curtin et al.	Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials	2010
Dr Agata Rozanska Dr Evan Mulligan Huw Thomas Deborah Castelbuono Professor Deborah Tweddle et al.	[abstract] Central nervous system (CNS) penetration, poly-ADP ribose polymerase (PARP) inhibition and enhancement of temozolomide activity against childhood medulloblastoma by AG-014699	2009
Huw Thomas Professor Nicola Curtin	Exploiting Homologous recombination repair defects in cancer cells	2009
Dr Agata Rozanska Huw Thomas Dr Evan Mulligan Dr Yvette Drew Deborah Castelbuono et al.	Inhibition of Poly (ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma	2009
Huw Thomas Dr Kappusamy Saravanan Lan Wang Mei Lin Dr Julian Scott Northen et al.	Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity	2009
Dr Steven Darby Huw Thomas Professor Craig Robson Professor Hing Leung Dr Marie Mathers et al.	Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical disease	2009
Huw Thomas Suzanne Kyle Tim Robson Professor Nicola Curtin	Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?	2009
Professor Herbie Newell Huw Thomas Lan Wang Dr Celine Roche Dr Ian Hardcastle et al.	[abstract] Preclinical in vitro and in vivo evaluation of the cyclin dependent kinase 2 inhibitor NU6102 and a water pro-drug NU6301	2008
Huw Thomas Professor Nicola Curtin	Chemosensitisation by tricyclic poly(ADP-ribose) polymerase (PARP) inhibitors in vivo: More than just DNA repair? [abstract]	2008
Suzanne Kyle Huw Thomas Dr Jane Mitchell Professor Nicola Curtin	Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer	2008
Huw Thomas Gordon Taylor Professor Herbie Newell Professor Alan Boddy	An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed	2007
Dr Jane Renwick Gordon Taylor Huw Thomas Professor Alan Boddy Dr Chris Redfern et al.	Molecular targeting of retinoic acid metabolism in neuroblastoma: The role of the CYP26 inhibitor R116010 in vitro and in vivo	2007
Professor Steven Clifford Rachel Daniel Dr Agata Rozanska Huw Thomas Professor Alan Boddy et al.	Preclinical evaluation of the POLY-ADP ribose polymerase 1 (PARP-1) inhibitor AG014699 in combination with topotecan and temozolomide for the treatment of medulloblastoma and neuroblastoma	2007
Huw Thomas Dr Christopher Calabrese Michael Batey Suzanne Kyle Professor Herbie Newell et al.	Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial	2007
Professor Gareth Veal Julie Errington Huw Thomas Professor Alan Boddy	Biliary excretion of etoposide in children with cancer	2006
Huw Thomas Dr Christopher Calabrese Professor Herbie Newell Lan Wang Professor Nicola Curtin et al.	Identification of a PARP inhibitor for clinical trial: Preclinical studies	2006
Dr Yan Zhao Huw Thomas Michael Batey Dr Ian Cowell Professor Roger Griffin et al.	Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441	2006
Huw Thomas Kathleen Parker Suzanne Kyle Professor Nicola Curtin	Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase	2005
Dr Christopher Calabrese Michael Batey Professor Alan Calvert Professor barbara Durkacz Suzanne Kyle et al.	Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361	2004
Dr Christopher Calabrese Professor Nicola Curtin Suzanne Kyle Huw Thomas Lan Wang et al.	Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1- hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase	2004
Dr Christopher Calabrese Michael Batey Huw Thomas Professor barbara Durkacz Lan Wang et al.	Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: Chemopotentiation and pharmacological studies	2003
Huw Thomas Gordon Taylor Professor Herbie Newell Professor Alan Boddy	Potentiation of raltitrexed (RTX) in vitro by thymidine phosphorylase (TP) and TP distribution in vivo	2003
Dr Christopher Calabrese Professor Nicola Curtin Suzanne Kyle Huw Thomas Lan Wang et al.	Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis, and X-ray cocrystal structure	2002
Huw Thomas Mike Cole Suzanne Elliott Professor Herbie Newell Professor Alan Calvert et al.	Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide	2002
Huw Thomas Gordon Taylor Professor Herbie Newell Professor Alan Boddy	The in vivo distribution of a CEA directed antibody conjugated to thymidine phosphorylase	2002
Professor Nicola Curtin Dr Stephen Barton Michael Batey Dr Christopher Calabrese Professor Alan Calvert et al.	Anti-cancer chemosensitization in vitro and in vivo by a novel potent poly(ADP-ribose) polymerase (PARP1) inhibitor, TBI-361.	2001
Gordon Taylor Huw Thomas Professor Herbie Newell Professor Nicola Curtin	Hypoxanthine transport in human tumour cell lines. Relationship to the inhibition of hypoxanthine rescue by dipyridamole	2001
Peter Smith Huw Thomas Hannah Barlow Professor Roger Griffin Emeritus Professor Bernard Golding et al.	In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity	2001
Professor Alan Boddy Melanie Griffin Julieann Sludden Huw Thomas Kevin Fishwick et al.	Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer	2001
Peter Smith Huw Thomas Hannah Barlow Professor Roger Griffin Emeritus Professor Bernard Golding et al.	In vitro activity and in vivo pharmacology of two novel nucleoside transport inhibitors, NU3108 and NU3121	2000
Dr Christopher Calabrese Professor Nicola Curtin Michael Batey Huw Thomas Suzanne Kyle et al.	Design and evaluation of novel potent inhibitors of poly (ADP-ribose) polymerase	2000
Professor Alan Boddy Melanie Griffin Julieann Sludden Huw Thomas Kevin Fishwick et al.	Paclitaxel and carboplatin dose-intensity and duration of infusion in the treatment of ovarian cancer	2000
Huw Thomas Professor Alan Calvert Professor Alan Boddy	Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours	2000
Huw Thomas Professor Alan Boddy Professor Andrew Pearson Professor Herbie Newell	Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial	2000
Dr Christopher Calabrese Huw Thomas Alex White	Preclinical pharmacology of novel potent inhibitors of PARP	1999
Dr Christopher Calabrese Huw Thomas Michael Batey Professor Nicola Curtin Professor Roger Griffin et al.	Preclinical pharmacology of novel substituted benzimidazoles - potent inhibitors of poly (ADP-ribose) polymerase	1999
Professor Gareth Veal Professor Alan Boddy Huw Thomas Annie Parry Professor Andrew Pearson et al.	Real-time monitoring of carboplatin pharmacokinetics in paediatric patients receiving high dose chemotherapy	1999
Professor Alan Boddy Huw Thomas	High dose cyclosporin with etoposide - Toxicity and pharmacokinetic interaction in children with solid tumours	1998
Huw Thomas Professor Alan Boddy Professor Andrew Pearson Professor Herbie Newell	Validation of pharmacologically-guided dosing of carboplatin in paediatric patients	1998
Professor Alan Boddy Huw Thomas Lynsey Robson Professor Alan Calvert	A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer	1997
Professor Alan Boddy Huw Thomas	RMP-7. Potential as an adjuvant to the drug treatment of brain tumours	1997
Professor Steve Wedge Fiona Chapman Gordon Taylor Huw Thomas Professor Alan Boddy et al.	A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid	1996
Professor Herbie Newell Huw Thomas Professor Alan Calvert	Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters	1996
Professor Alan Boddy Huw Thomas Professor Herbie Newell Professor Alan Calvert Lynsey Robson et al.	Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: A cancer research campaign phase I/II committee study	1996
Professor Alan Calvert Professor Alan Boddy Dr Andrew Hughes Lynsey Robson Huw Thomas et al.	Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.	1995